🔗 Share this article

Given that the United States undertakes unprecedented changes to its immunization schedules, one figure appears unexpectedly: Høeg, a US-based sports medicine doctor and public health researcher who initially gained attention by casting doubt on Covid vaccinations throughout the pandemic and has focused upon potential fatalities after COVID-19 vaccination in her recent tenure at the FDA.

Scheduled Changes to Pediatric Immunization Schedule

Agency leaders had intended to reveal major changes to the pediatric vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a significant shift that would put the US at odds with much of the international standard with no evidence for benefit. The announcement has been pushed back until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

A New Direction at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the agency – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting some pediatric immunization guidelines in the US to become more like the Danish model, a country with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – rather than medication approval.

Doubts Over Expertise

The appointee has little discernible background in pharmaceutical research, oversight or administrative roles, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp legal statutes and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that former directors who ran CBER have had.”

The drug center has an vast workload at the agency, she emphasized.

“Everybody just focuses on the innovative therapies, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and more, and every single one need to be looked after,” she explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership aspect to the job, which manages over 5,000 personnel. “It’s a massive administrative position, if you do it right,” Woodcock concluded.

Response and Controversial Policies

When asked about questions about Høeg’s qualifications and whether this appointment represents greater collaboration among regulatory chiefs on immunizations, a press secretary said that the “questions rely on inaccurate presumptions”.

“Her experience aligns with the functions of her job,” the spokesperson said, citing the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's recently launched priority voucher program, a contentious expedited drug-approval program that apparently troubled her preceding directors. “By what process are these therapies being selected for this fast-track system? Who takes the choices?” Howard asked. “There’s a lot of confidentiality going on at the agency right now.”

Overall, he stated, “the agency looks to be trending towards less stringent oversight of all drugs, aside from vaccines.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, Howard said. She released a research paper using unconfirmed public submissions to estimate the frequency of heart inflammation after COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the current federal leadership encompassed changing regulations for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her conclusions and tailors the evidence to retrofit the evidence in a highly misleading, untruthful fashion,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg joined fellow skeptics, {like|